NCT02031471View on ClinicalTrials.gov

TOSCARA Study: A Study of Subcutaneous Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis Naïve to RoActemra/Actemra Treatment

PHASE3CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Rheumatoid Arthritis
Interventions
DRUG

tocilizumab

Fixed dose of 162 mg subcutaneously weekly

Trial Locations (17)

1020

Brussels

1050

Brussels

1070

Brussels

2610

Wilrijk

2763

Luxembourg

2820

Bonheiden

3600

Genk

4000

Liège

6000

Gilly (Charleroi)

6041

Gosselies

7100

Haine-Saint-Paul

8310

Assebroek

8340

Sijsele

8800

Roeselare

9000

Ghent

9100

Sint-Niklaas

9300

Aalst

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02031471 - TOSCARA Study: A Study of Subcutaneous Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis Naïve to RoActemra/Actemra Treatment | Biotech Hunter | Biotech Hunter